COVID-19 Infection in Patients with Humoral Immunodeficiency: A Case Series and Literature Review.
Allergy Rhinol (Providence)
; 13: 21526575221096044, 2022.
Article
in English
| MEDLINE | ID: covidwho-1817130
ABSTRACT
Background:
The coronavirus 2019 disease (COVID-19) has infected many individuals worldwide and continues to pose a significant threat to those with weakened immune systems. The data evaluating the clinical outcomes of patients with humoral immunodeficiencies that contract COVID-19 is limited and conflicting.Objective:
To describe the clinical outcomes of COVID-19 infections in patients with primary humoral immunodeficiency and compare results to current literature.Methods:
We conducted a retrospective cohort review on 15 patients with a humoral immunodeficiency defined as Common Variable Immunodeficiency, Specific Antibody Deficiency, or unspecified hypogammaglobulinemia, who contracted COVID-19. Severity scores were determined to evaluate the clinical outcomes of these patients.Results:
Of our 15-patient cohort, 33% of individuals with a humoral immunodeficiency infected with COVID-19 had moderate to severe disease, requiring hospitalization or resulting in death. COVID-19 mortality rate was found to be 7%. All 5 of our patients with severe COVID-19 infection had at least 1 comorbidity or risk factor.Conclusion:
Within our cohort of humoral immunodeficient patients infected with COVID-19, we found a higher rate of moderate to severe COVID-19 infection and worse clinical outcomes, particularly in patients with comorbidities or risk factors.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Reviews
Language:
English
Journal:
Allergy Rhinol (Providence)
Year:
2022
Document Type:
Article
Affiliation country:
21526575221096044
Similar
MEDLINE
...
LILACS
LIS